Hunter Syndrome Treatment Market Size, Share & Industry Analysis, By Treatment (Enzyme Replacement Therapy (ERT), and Others), By Route of Administration (Intravenous, and Intracerebroventricular (ICV)/ Intrathecal), By End User (Hospitals, Specialty Clinics and Others), and Regional Forecast, 2019-2026 (Includes COVID-19 Business Impact)

  • TBI241787
  • August 19, 2020
  • Global
  • 132 pages
  • ROIF Expert
                                          

We have updated Hunter Syndrome Treatment Market with respect to COVID-19 Business Impact. Inquire before buying This report focuses on the Hunter Syndrome Treatment market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Hunter Syndrome Treatment market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.

Global Hunter Syndrome Treatment Market: Segment Analysis

The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.

Global Hunter Syndrome Treatment Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.

Global Hunter Syndrome Treatment Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.

List of Companies Profiled

Key Product offering and core focus on rare diseases of Shire (Takeda Pharmaceutical Company Limited), to help the company to retain a leading position Competition landscape of Hunter syndrome treatment market depicts a monopoly dominated by Shire (now owned by Takeda Pharmaceutical Company Limited). The key and only product offering of Elaprase (idursulfase), its efficiency in terms of treatment outcomes and also its indispensability in key markets, are prominent factors responsible for the dominance of the company. However, certain prominent clinical stage biopharmaceutical companies such as ArmaGen, and REGENXBIO Inc., have entered the monopoly market of Hunter syndrome treatment with their potential drug candidates. This is projected to positively impact the global market as these companies are poised to gain market share during the forecast period through key regulatory approvals.

LIST OF KEY COMPANIES PROFILED:

  • Shire (Takeda Pharmaceutical Company Limited)
  • Denali Therapeutics
  • ArmaGen
  • Inventiva
  • Green Cross Corp. (GC Pharma)
  • CANbridge Life Sciences Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • REGENXBIO Inc.
  • Sangamo Therapeutics
  • Others

KEY INDUSTRY DEVELOPMENTS:

December 2019

-REGENXBIO Inc., a clinical stage biotechnology company, announced positive interim data from the Phase I/II trial of RGX-121 for the treatment of Hunter syndrome.

July 2019

-CANBridge Pharmaceuticals Inc., a Chinese biopharmaceutical company, submitted a New Drug Application (NDA) for Hunterase for the treatment of Hunter syndrome in China.

September 2018

-ArmaGen, a clinical stage biotechnology company, announced a drug candidate called AGT-182, which is currently in Phase I clinical trials for the ˜safety and dose ranging study of insulin receptor MoAb-IDS fusion protein in patients with Hunter syndrome.

REPORT COVERAGE

The Hunter syndrome treatment market report provides a detailed analysis of the market and focuses on key aspects such as prevalence of Hunter syndrome, by key regions, 2018, pipeline analysis, key industry developments, regulatory scenario by key regions, overview of emerging treatments for Hunter syndrome, and, reimbursement scenario by key regions. Besides this, the report offers insights into the market trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market over the recent years.

Report Scope & Segmentation

Segmentation

By Treatment

  • Enzyme Replacement Therapy (ERT)
  • Others

By Route of Administration

  • Intravenous
  • Intracerebroventricular (ICV)/ Intrathecal

By End User

  • Hospitals
  • Specialty Clinics
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
  • Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
  • Rest of the World
 

Table of Content
Chapter 1. Methodology and Scope 
1.1. Research Methodology 
1.2. Research Scope & Assumptions 
1.3. List of Data Sources
Chapter 2. Executive Summary
Chapter 3. Hunter Syndrome Treatment Market
3.1. Market Segmentation 
3.2. Market Size and Growth Prospects, 2019 - 2029 
3.3. Value Chain Analysis 
3.4. Market Dynamics 
3.4.1. Market driver analysis 
3.4.2. Market restraint analysis
Chapter 4. Market Size by Application
4.1 Hunter Syndrome Treatment Market Consumption by Application (2015-2020) 
4.2 Hunter Syndrome Treatment Market Consumption by Application (2020-2029) 

|  read more...

Request a sample

Fill below form to request a sample

Enquiry

Please fill this form to enquire before buying

Discount

You can request for discount regarding the report by using below form